Clearside Biomedical Inc
NASDAQ:CLSD 11:54:56 AM EDT
| Market Cap (Intraday) | 62.17M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.80 |
| 50-Day MA | $0.82 |
| 200-Day MA | $0.98 |
Clearside Biomedical Inc Stock, NASDAQ:CLSD
900 North Point Parkway, Suite 200, Alpharetta, Georgia 30005
United States of America
Phone: +1.678.270.3631
Number of Employees: 30
Description
Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. Its SCS microinjector enables a simple, repeatable, in-office procedure to deliver treatments directly to the macula, retina, or choroid, potentially helping to preserve and improve vision in patients with serious eye diseases. Its pipeline includes CLS-AX, an Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.